5z1c
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | The | + | ==The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4== |
| - | + | <StructureSection load='5z1c' size='340' side='right' caption='[[5z1c]], [[Resolution|resolution]] 1.45Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5z1c]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5Z1C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5Z1C FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZXI:1-(4-iodophenyl)methanamine'>ZXI</scene></td></tr> | |
| - | [[ | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr> |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5z1c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5z1c OCA], [http://pdbe.org/5z1c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5z1c RCSB], [http://www.ebi.ac.uk/pdbsum/5z1c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5z1c ProSAT]</span></td></tr> |
| - | [[Category: Huang, M | + | </table> |
| - | [[Category: Jiang, L | + | == Disease == |
| + | [[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: U-plasminogen activator]] | ||
| + | [[Category: Huang, M D]] | ||
| + | [[Category: Jiang, L G]] | ||
| + | [[Category: Luo, Z P]] | ||
[[Category: Zhang, X]] | [[Category: Zhang, X]] | ||
| + | [[Category: Halogen bonding]] | ||
| + | [[Category: Hydrolase]] | ||
| + | [[Category: P1 group]] | ||
| + | [[Category: Protease inhibitor]] | ||
| + | [[Category: Serine protease]] | ||
| + | [[Category: Upa]] | ||
Revision as of 08:12, 26 December 2018
The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4
| |||||||||||
